- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946783
A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
A Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Administration, Dose-escalation Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics Characteristics and the Effect of Food on Pharmacokinetics of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Sun Haibin
- Phone Number: +8618200237928
- Email: sunhaibin@zenitar.cn
Study Locations
-
-
-
Melbourne, Australia
- Nucleus Network Pty Ltd Commercial Road
-
Contact:
- Ofer Gonen, Doctor
- Phone Number: 03 8593 9801
- Email: o.gonen@nucleusnetwork.com.au
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- i, Healthy adult participants, regardless of gender, aged between 18 and 65 years old when the informed consent is signed; ii,Male participants with a body weight of >= 50.0 kg, female participants with a body weight of >= 45.0 kg; iii, Those who can understand the informed consent form, voluntarily participate in the trial and sign the informed consent form.
Exclusion Criteria:
- Individuals with allergic constitution, or those with a history of clinically significant food, drug allergies or other allergic reactions as determined by the investigators; or those who are known to be allergic to NLRP3 inhibitors or to the excipient ingredients of the IP;
- Have any prior diagnosis of diabetes mellitus;
- Those with a positive result in any of the following tests: HIV antibody, syphilis spirochete antibody, hepatitis B surface antigen, hepatitis C antibody, or interferon-gamma release assay;
- Those who donated blood or lost blood >=400 mL within 30 days prior to screening, or received blood transfusion;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single-ascending Dose (SAD) study and Food Effect (FE) study
|
The SAD portion of the study consists of 5 cohorts. Dosing in these cohorts will precede sequentially: 5 mg, 10 mg, 25 mg, 40 mg and 50 mg cohorts. |
|
Experimental: Multiple-ascending Doses (MAD) study
|
The MAD portion of the study consists of 3 cohorts. Dosing in these cohorts will precede sequentially:10 mg, 25 mg and 40 mg cohorts. |
|
Experimental: Obesity with cardiovascular risk study
|
This study intends to set up 2 dose cohorts, temporarily as follows: 1) 10 mg QD cohort, 2) 25 mg QD cohort. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events
Time Frame: Day 1 to Day 21
|
including hematology, blood biochemistry, urinalysis, and coagulation function |
Day 1 to Day 21
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ZL65 Pharmacokinetics (PK):Cmax
Time Frame: 0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):Tmax
Time Frame: 0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):AUC0-t
Time Frame: 0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):t1/2
Time Frame: 0-144 hours
|
0-144 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ofer Gonen, Doctor, Nucleus Network Pty Ltd Commercial Road
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Investigative Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Physiological Phenomena
- Biochemical Phenomena
- Chemical Phenomena
- Physical Examination
- Body Size
- Body Weights and Measures
- Body Constitution
- Anthropometry
- Metabolism
- Body Fat Distribution
- Body Composition
- mycophenolic adenine dinucleotide
- Sagittal Abdominal Diameter
- Adiposity
Other Study ID Numbers
- O-ZL65-PI-I
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.